362 / 671
•
Is SBRT replacing systemic therapy?
•
Or should they be combined?
•
TOAD trial
(Duchesne et al, ASCO 2015): immediate versus delayed ADT
at PSA relapse after definitive therapy
–
HR=0.55 (CI: 0.30-1.00)
•
CHAARTED-
(Sweeney et al NEJM 2015): ADT+docetaxel versus ADT alone
in advanced stage hormone sensitive PCa
–
HR=0.61 (CI: 0.47-0.80)
–
m-OS: 58 and 44 months, respectively
•
STAMPEDE
(James et al Lancet 2016): SOC+docetaxel versus SOC in
advanced stage hormone sensitive PCa
–
HR=0·78 (CI: 0·66–0·93)
•
Combination with immune stimulating agents
SBRT of prostate cancer and systemic therapies